CytImmune Sciences, Inc. operates as a clinical stage nanomedicine company that discovers, develops, and commercializes multifunctional tumor-targeted therapies. The company develops Aurimune, a nanomedicine platform that gets into the tumor and breaks down its defenses. It is engineered to travel safely and stealthily through the body and enter tumors through their most vulnerable points – the leaky blood vessels that make up the nutritional support structures. CytImmune Sciences, Inc. was founded in 1988 and is based in Rockville, Maryland.